RET原癌基因在甲状腺癌中的研究进展

doi:10.19586/j.2095-2341.2023.0002

生物技术进展 ›› 2023, Vol. 13 ›› Issue (6): 895-899.DOI: 10.19586/j.2095-2341.2023.0002

• 进展评述 • 上一篇

RET原癌基因在甲状腺癌中的研究进展

焦佳媛(), 邢久歌, 柴宝山()

沈阳化工研究院有限公司医药研究室，沈阳 110021

收稿日期:2023-01-10 接受日期:2023-09-21 出版日期:2023-11-25 发布日期:2023-12-12
通讯作者: 柴宝山
作者简介:焦佳媛E-mail: jiaojiayuan@sinochem.com；
基金资助:
沈阳化工研究院资助项目(99000029)

Research Progress on RET Oncogene in Thyroid Carcinoma

Jiayuan JIAO(), Jiuge XING, Baoshan CHAI()

Pharmaceutical Research Laboratory，Shenyang Research Institute of Chemical Industry Co. ，Ltd. ，Shenyang 110021，China

Received:2023-01-10 Accepted:2023-09-21 Online:2023-11-25 Published:2023-12-12
Contact: Baoshan CHAI

摘要/Abstract

摘要：

原癌基因RET（rearranged during transfection）在1985年被鉴定，随后，在甲状腺乳头状癌（papillary thyroid carcinoma, PTC）中发现了不同类型的RET/PTC染色体重排。在遗传性和散发性的甲状腺髓样癌（medullary thyroid carcinoma, MTC）中发现RET点突变基因。与PTC中RET的变化存在不同，MTC中RET的活化主要通过激活点突变。RET不同类型的重排活化与甲状腺癌的高发密切相关，RET不同的活化机制需对应不同的治疗对策。讨论了RET原癌基因在甲状腺乳头状癌和甲状腺髓样癌中的致病、诊断和预后的作用，以期为RET活化引起的甲状腺癌的治疗提供理论依据。

关键词: 原癌基因重排, 甲状腺髓样癌, 甲状腺乳头状癌, 致病, 诊断, 预后

Abstract:

Proto-oncogene rearranged during transfection （RET） was identified in 1985， and then， the different types of RET/PTC rearrangement of chromosomes were discovered in papillary thyroid carcinoma （PTC）. Activating point mutations in the RET proto-oncogene were discovered in both hereditary and sporadic forms of medullary thyroid carcinoma （MTC）. Different from the change of RET in PTC， the activation of RET in MTC is mainly through the activation point mutation. Thus， the different types of rearrangement activation of RET are closely related to the high incidence of thyroid cancer. Different activation mechanisms of RET will lead to different treatment strategies. In this review， we discussed the role of RET proto-oncogenes in the pathogenesis， diagnosis and prognosis of PTC and MTC， which was expected to provide reference for the thyroid carcinoma caused by RET activation.

Key words: rearranged during transfection, medullary thyroid carcinoma, papillary thyroid carcinoma, pathogenesis, diagnosis, prognosis

中图分类号:

Q279

焦佳媛, 邢久歌, 柴宝山. RET原癌基因在甲状腺癌中的研究进展[J]. 生物技术进展, 2023, 13(6): 895-899.

Jiayuan JIAO, Jiuge XING, Baoshan CHAI. Research Progress on RET Oncogene in Thyroid Carcinoma[J]. Current Biotechnology, 2023, 13(6): 895-899.

参考文献 47

1	PELLEGRITI G, FRASCA F, REGALBUTO C, et al.. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors[J/OL]. J. Cancer Epidemiol., 2013, 2013: 965212[2023-02-20]. .
2	ELISEI R, PINCHERA A. Advances in the follow-up of differentiated or medullary thyroid cancer[J]. Nat. Rev. Endocrinol., 2012, 8(8): 466-475.
3	SAK S D. Variants of papillary thyroid carcinoma: multiple faces of a familiar tumor[J]. Turk. Patoloji. Derg., 2015, 31(S1): 34-47.
4	GRIECO M, SANTORO M, BERLINGIERI M T, et al.. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas[J]. Cell, 1990, 60(4): 557-563.
5	MULLIGAN L M, KWOK J B, HEALEY C S, et al.. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A[J]. Nature, 1993, 363(6428): 458-460.
6	ENG C, SMITH D P, MULLIGAN L M, et al.. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours[J]. Hum. Mol. Genet., 1994, 3(2): 237-241.
7	TAKAHASHI M, RITZ J, COOPER G M. Activation of a novel human transforming gene, ret, by DNA rearrangement[J]. Cell, 1985, 42(2): 581-588.
8	ARIGHI E, BORRELLO M G, SARIOLA H. RET tyrosine kinase signaling in development and cancer[J]. Cytokine Growth Factor Rev., 2005, 16(4-5): 441-467.
9	ANDERS J, KJAR S, IBÁÑEZ C F. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site[J]. J. Biol. Chem., 2001, 276(38): 35808-35817.
10	FRANK-RAUE K, RONDOT S, RAUE F. Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC[J]. Mol. Cell. Endocrinol., 2010, 322(1-2): 2-7.
11	BALOH R H, ENOMOTO H, JOHNSON E MJR, et al.. The GDNF family ligands and receptors-implications for neural development[J]. Curr. Opin. Neurobiol., 2000, 10(1): 103-110.
12	RAUE F, FRANK-RAUE K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management[J]. Hormones, 2009, 8(1): 23-28.
13	HIROKAWA N, NODA Y, TANAKA Y, et al.. Kinesin superfamily motor proteins and intracellular transport[J]. Nat. Rev. Mol. Cell Biol., 2009, 10(10): 682-696.
14	KIMURA E T, NIKIFOROVA M N, ZHU Z, et al.. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma[J]. Cancer Res., 2003, 63(7): 1454-1457.
15	CIAMPI R, KNAUF J A, KERLER R, et al.. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer[J]. J. Clin. Invest., 2005, 115(1): 94-101.
16	UCHINO S, NOGUCHI S, YAMASHITA H, et al.. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type[J]. Jpn J. Cancer Res., 1999, 90(11): 1231-1237.
17	MULLIGAN L M, MARSH D J, ROBINSON B G, et al.. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the international RET mutation consortium[J]. J. Intern. Med., 1995, 238(4): 343-346.
18	HANSFORD J R, MULLIGAN L M. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis[J]. J. Med. Genet., 2000, 37(11): 817-827.
19	VITA D. Molecular biology of the MEN2 gene[J]. J. Intern. Med., 1998, 243(6): 505-508.
20	CERRATO A, DE FALCO V, SANTORO M. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets[J]. J. Mol. Endocrinol., 2009, 43(4): 143-155.
21	ORIOLA J, HALPERIN I, RIVERA-FILLAT F, et al.. The finding of a somaticdeletion in RET exon 15 clarified the sporadic nature of amedullary thyroid carcinoma suspected to be familial[J]. J. Endocrinol. Invest., 2002, 25(1): 25-31.
22	CECCHERINI I, PASINI B, PACINI F, et al.. Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene[J]. Oncogene, 1997, 14(21): 2609-2612.
23	MARSH D J, LEAROYD D L, ANDREW S D, et al.. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma[J]. Clin. Endocrinol., 1996, 44(3): 249-257.
24	KATO M, IWASHITA T, AKHAND A A, et al.. Molecular mechanism of activation and superactivation of Ret tyrosine kinases by ultraviolet light irradiation[J]. Antioxid. Redox Signal., 2000, 2(4): 841-849.
25	KATO M, IWASHITA T, TAKEDA K, et al.. Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases[J]. Mol. Biol. Cell, 2000, 11(1): 93-101.
26	SAENKO V, ROGOUNOVITCH T, SHIMIZU-YOSHIDA Y, et al.. Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid carcinoma from externally irradiated patient[J]. Mutat. Res., 2003, 527(1-2): 81-90.
27	SALASSIDIS K, BRUCH J, ZITZELSBERGER H, et al.. Translocation t(10;14)(q11.2: Q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma[J]. Cancer Res., 2000, 60(11): 2786-2789.
28	CORVI R, BERGER N, BALCZON R, et al.. RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma[J]. Oncogene, 2000, 19(37): 4236-4242.
29	CIAMPI R, GIORDANO T J, WIKENHEISER-BROKAMP K, et al.. HOOK₃-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma[J]. Endocr. Relat. Cancer, 2007, 14(2): 445-452.
30	NETWORK C G A R, AGRAWAL N, AKBANI R, et al.. Integrated genomic characterization of papillary thyroid carcinoma[J]. Cell, 2014, 159(3): 676-690.
31	KHAN M S, QADRI Q, MAKHDOOMI M J, et al.. RET/PTC gene rearrangements in thyroid carcinogenesis: assessment and clinico-pathological correlations[J]. Pathol. Oncol. Res., 2020, 26(1): 507-513.
32	SANTORO M, MOCCIA M, FEDERICO G, et al.. RET gene fusions in malignancies of the thyroid and other tissues[J/OL]. Genes, 2020, 11(4): 424[2023-02-20]. .
33	STAUBITZ J I, SCHAD A, SPRINGER E, et al.. Novel rearrangements involving the RET gene in papillary thyroid carcinoma[J]. Cancer Genet., 2019, 230: 13-20.
34	MARGRAF R L, CROCKETT D K, KRAUTSCHEID P M F, et al.. Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations[J]. Hum. Mutat., 2009, 30(4): 548-556.
35	ELISEI R, ROMEI C, RENZINI G, et al.. The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center[J]. J. Clin. Endocrinol. Metab., 2012, 97(2): 426-435.
36	BALOCH Z W, LIVOLSI V A. Fine-needle aspiration of the thyroid: today and tomorrow[J]. Best Pract. Res. Clin. Endocrinol. Metab., 2008, 22(6): 929-939.
37	COOPER D S, DOHERTY G M, HAUGEN B R, et al.. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11): 1167-1214.
38	NIKIFOROV Y E. Molecular analysis of thyroid tumors[J]. Mod. Pathol., 2011, 24(S2): 34-43.
39	MOSES W, WENG J, SANSANO I, et al.. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy[J]. World J. Surg., 2010, 34(11): 2589-2594.
40	KIM B H, KIM I J. Recent updates on the management of medullary thyroid carcinoma[J]. Endocrinol. Metab., 2016, 31(3): 392-399.
41	KLOOS R T, ENG C, EVANS D B, et al.. Medullary thyroid cancer: management guidelines of the American Thyroid Association[J]. Thyroid, 2009, 19(6): 565-612.
42	ROMAN S, LIN R, SOSA J A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases[J]. Cancer, 2006, 107(9): 2134-2142.
43	刘方舟. 循环BRAF突变基因联合其它检测在甲状腺乳头状癌诊断及预后作用的实验研究[D]. 郑州: 郑州大学, 2010.
44	BALLERINI P, STRUSKI S, CRESSON C, et al.. RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation[J]. Leukemia, 2012, 26(11): 2384-2389.
45	NIKIFOROV Y E, ROWLAND J M, BOVE K E, et al.. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children[J]. Cancer Res., 1997, 57(9): 1690-1694.
46	ROMEI C, CIAMPI R, FAVIANA P, et al.. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer[J]. Endocr. Relat. Cancer, 2008, 15(2): 511-520.
47	JARGIN S V. RET/PTC3 rearrangement in papillary thyroid carcinoma: possible marker of tumor progression[J]. Ann. Surg., 2017, 266(6): e120-e121.

[1]	王彦容, 郭元彪. 基于铁死亡相关LncRNA构建肝细胞癌预后模型的研究[J]. 生物技术进展, 2023, 13(3): 473-481.
[2]	程陈恩泽, 贾明宏, 李月影. 食源性致病菌核酸标准物质的研究进展[J]. 生物技术进展, 2023, 13(2): 195-200.
[3]	李冠群, 梁超杰, 夏峰. 基于甲基化组学数据建立并验证肝细胞癌预后评价模型研究[J]. 生物技术进展, 2023, 13(2): 282-290.
[4]	赵文卓, 李成勋, 胡作建, 余红秀. 功能核酸用于致病菌检测的研究进展[J]. 生物技术进展, 2023, 13(1): 30-38.
[5]	王彩虹, 陈剑飞, 鞠久君, 朱雪洁, 王彩霞. PKM2促进肿瘤发展的作用机制研究[J]. 生物技术进展, 2022, 12(3): 411-418.
[6]	雍嘉欣, 韦权峰, 刘尚辉. 基于TCGA和GEO数据库的胃癌lncRNA筛选与ceRNA网络构建[J]. 生物技术进展, 2022, 12(1): 149-157.
[7]	郭博远, 赵鹏翔, 王惠, 王振, 姚婷婷, 刘梦昱, ADZAVON Yao Mawulikplimi, 谢飞. 拉曼光谱在皮肤领域的研究进展[J]. 生物技术进展, 2022, 12(1): 44-49.
[8]	段凯莉, 江聪, 王光辉. 禾谷镰刀菌蛋白激酶研究进展[J]. 生物技术进展, 2021, 11(5): 618-627.
[9]	李乐, 于晓清, 李翘楚, 于道德, 邹琰, 叶海斌, 吴海一, 刁菁. 我国鲑鳟鱼类养殖常见流行疫病研究概况[J]. 生物技术进展, 2021, 11(4): 462-470.
[10]	王子健, 陈颖钰, 胡长敏, 郭爱珍. 我国兽用诊断试剂产业现状与未来趋势[J]. 生物技术进展, 2021, 11(4): 471-475.
[11]	卢海强,焦新雅,,吴思源,王娅丽,刘璐,程书梅,张晓,苏晓峰. 数字PCR在食源性致病菌检测中的应用进展[J]. 生物技术进展, 2021, 11(3): 260-268.
[12]	白小莲,爱军. 生物传感器在食源性致病菌大肠杆菌O157∶H7检测中的应用进展[J]. 生物技术进展, 2021, 11(3): 269-278.
[13]	玄琦月,韩雪,付英梅,. 肺外结核病微生物学诊断方法的研究和应用进展[J]. 生物技术进展, 2021, 11(1): 47-53.
[14]	高海明,赵彦艳. 二代及三代测序技术在遗传学诊断中的应用进展[J]. 生物技术进展, 2020, 10(6): 646-654.
[15]	陈硕,高佳奇,王迪,龙艳,李亮,张晓. DNA四面体纳米结构及其在生物技术领域的应用进展[J]. 生物技术进展, 2020, 10(6): 661-667.

RET原癌基因在甲状腺癌中的研究进展

Research Progress on RET Oncogene in Thyroid Carcinoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 47

相关文章 15

编辑推荐

Metrics

本文评价